Trials / Completed
CompletedNCT06393348
Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
2 weeks screening period, 3 weeks run-in period, 16 weeks double-blind treatment period, to evaluate the Safety and Efficacy of HRS-7535 in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and SGLT2i.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-7535 | HRS-7535 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2024-05-17
- Primary completion
- 2024-11-15
- Completion
- 2025-03-13
- First posted
- 2024-05-01
- Last updated
- 2025-12-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06393348. Inclusion in this directory is not an endorsement.